Clinical trial
Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced…
NCT00489983 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00489983 |
|---|---|
| Title | Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy |
| Official title | A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, gemcitabine |
| Enrollment | 91 |
| Start date | Jul 1, 2003 |
| Completion | Mar 1, 2005 |
| First posted | Jun 22, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | Germany, Italy, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: